Protein kinase C delta (PRKCD) (PRKCD)

Protein kinase C delta (PRKCD) is a member of the novel protein kinase C (nPKC) subfamily, characterized by its calcium-independent but diacylglycerol (DAG)-dependent activation mechanism [1, 2]. As a ubiquitous serine/threonine kinase, PRKCD serves as a critical node in various signal transduction pathways, regulating fundamental processes such as apoptosis, cell cycle progression, and immune cell homeostasis [2, 5]. Its biological role is notably complex and context-dependent; it can function as either a tumor suppressor or an oncogene, and as a pro-apoptotic or anti-apoptotic mediator depending on the specific cellular environment and stimulus [5, 11]. In the immune system, PRKCD is essential for maintaining B-cell tolerance, and its deficiency is a known cause of monogenic systemic lupus erythematosus (SLE) and other lymphoproliferative disorders [7, 8]. In oncology, dysregulated PRKCD signaling is associated with the progression and chemoresistance of several cancers, including breast, pancreatic, and colon malignancies [11, 14]. Therapeutic strategies targeting PRKCD primarily utilize small-molecule inhibitors, many of which are pan-PKC inhibitors, to modulate immune responses or induce cell death in malignant tissues [6, 10]. However, the target's multifaceted nature and its vital role in immune regulation pose significant challenges for achieving therapeutic precision and minimizing adverse effects [8, 10]. Sources: [1] UniProt (Q05655); [2] GeneCards; [3] Wikipedia; [4] PMC3779654; [5] PubMed 21406692; [6] DrugBank; [7] NCBI Gene 5580; [8] PMC3779654; [10] ResearchGate (PKC Family Review); [11] Frontiers in Oncology (Pan-Cancer Study); [14] Breast Cancer Research (PRKCD Variants).

Other names

PKC-deltaPKCDnPKC-deltaMAY1ALPS3CVID9Sphingosine-dependent protein kinase-1Tyrosine-protein kinase PRKCD

Inhibition of kinase activity through ATP-competitive binding or modulation of the regulatory domain to alter downstream phosphorylation signaling pathways [1, 2, 6].